PeptideStack
5.2kquestions
20kanswers
220users

Does headache at week six of retatrutide usually resolve without a dose change?

Asked 6 Sept 2024Modified 23 months agoViewed 37k times
38

The particulars: headache · six · retatrutide.

I have done this once and I suspect I got away with it rather than got it right.

For context: I keep records of every batch, every lot number and every result, so an answer that requires me to track something is fine.

What would you do, and what would you check afterwards?

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questionsharm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questionsretatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
shareeditfollowflag
GA
askedgrainne_ahearn50k386 Sept 2024
8Same situation here, so I will follow this one. – tare_weight 2 months ago
How long since the last increase? That is the first thing anyone will ask. – RP_C18 4 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 37k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.